There’s always a lot of anticipation about the “late breaker” session, which presents research that wasn’t available until the last mi...

AIDSmeds Founder Peter Staley interviewed Dr. Donald Kotler, Chief of Gastroenterology at St. Luke’s-Roosevelt Hospital.

Encouraging results from a second study were reported today.

Forty-eight week results from a phase II clinical trial of TNX-355, an HIV-entry inhibitor, were reported today at the XVI International AIDS...

Preliminary results from an ongoing clinical trial of MK-0518, Merck’s experimental integrase inhibitor, suggest that it has comparable anti-H...

Final data from a 48-week study comparing Norvir (ritonavir)-boosted Lexiva (fosamprenavir) to Kaletra (ritonavir-boosted lopinavir).

Results from a clinical trial presented at the XVI International AIDS Conference (IAC) indicate that maraviroc, Pfizer’s experimental entry in...

The AIDS Clinical Trials Group has reported results from a clinical trial of vicriviroc, an experimental entry inhibitor being developed by Sc...

AIDSmeds Founder Peter Staley interviewed Dr. Anthony Fauci, Director of NIAID at the NIH, and head of AIDS research for U.S. government.

According to the World Health Organization (WHO), more than one million people in sub-Saharan Africa are currently receiving HIV treatment.